预约演示

更新于：2025-12-14

Beijing Mabworks Biotech Co., Ltd.

www.mab-works.com

更新于：2025-12-14

概览

疾病领域	数量

肿瘤	24
血液及淋巴系统疾病	7
免疫系统疾病	7
内分泌与代谢疾病	5
神经系统疾病	1
感染	1

排名前五的药物类型	数量

单克隆抗体	14
双特异性抗体	4
双特异性T细胞结合器	3
ADC	2
生物药	1

排名前五的靶点	数量

CD47(CD47蛋白)	2
CLDN18.2(Claudin 18.2蛋白)	2
CD276(CD276抗原)	2
LAG3(淋巴细胞活化基因3蛋白)	1
PCSK9(前蛋白转化酶枯草杆菌蛋白酶Kexin-9)	1

关联

项与北京天广实生物技术股份有限公司相关的药物

Recombinant humanized monoclonal antibody MIL62 (Beijing InnoCare)

重组人源化单抗MIL62（北京诺诚健华）

靶点

CD20

作用机制

CD20抑制剂

在研机构

北京诺诚健华医药科技有限公司 [+1]

原研机构

北京诺诚健华医药科技有限公司

在研适应症

特发性膜性肾病 [+8]

非在研适应症

CD20阳性的B细胞非霍奇金淋巴瘤 [+2]

最高研发阶段申请上市

首次获批国家/地区-

首次获批日期-

MIL86

重组全人源单抗MIL86(Beijing Mabworks Biotech)

靶点

PCSK9

作用机制

PCSK9抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

MIL-97

靶点

CD40

作用机制

CD40激动剂

在研机构

中国医学科学院肿瘤医院 [+1]

原研机构

北京天广实生物技术股份有限公司

在研适应症

晚期胰腺腺癌 [+4]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

项与北京天广实生物技术股份有限公司相关的临床试验

NCT06232096

/ Recruiting临床1/2期

A Phase Ⅰ/Ⅱ Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of MBS314 Injection in Patients With Relapsed/Refractory Multiple Myeloma.

This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel asymmetric trivalent tri-specific humanized antibody, MBS314, administered by intravenous (IV) infusion in participants with relapsed or refractory multiple myeloma. This entry-to-human study is divided in 2 parts: a dose escalation part (Phase Ⅰa) and an expansion part (Phase Ⅰb/Ⅱ).

开始日期2024-02-22

申办/合作机构

北京天广实生物技术股份有限公司

NCT05806099

/ Recruiting临床1/2期

A Phase I/Ⅱ Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of MBS303 in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel T-Cell bispecific (TCB), MBS303, administered by intravenous (IV) infusion in participants with relapsed or refractory B-cell NHL. This entry-to-human study consists of 2 parts: a dose escalation part (Phase I) and an expansion part (Phase Ⅱ)

开始日期2023-06-28

申办/合作机构

北京天广实生物技术股份有限公司

NCT05862233

/ Active, not recruiting临床3期

A Phase Ⅲ Clinical Study to Evaluate the Safety and Efficacy of MIL62 Injection in Participants With Primary Membranous Nephropathy

This study will evaluate the efficacy, safety, pharmacokinetics(PK) ,pharmacodynamics（PD）and anti-drug antibodies（ADA） of MIL62 compared with cyclosporine in participants with primary membranous nephropathy (pMN).

开始日期2023-06-02

申办/合作机构

北京天广实生物技术股份有限公司

100 项与北京天广实生物技术股份有限公司相关的临床结果

登录后查看更多信息

0 项与北京天广实生物技术股份有限公司相关的专利（医药）

登录后查看更多信息

项与北京天广实生物技术股份有限公司相关的文献（医药）

2025-11-01·Journal for ImmunoTherapy of Cancer

Oncolytic virus-induced IL-1β ⁺ monocyte-IL-6 ⁺ CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer

Article

作者: Yu, Jufeng ; Wang, Jie ; Zhang, Hongkai ; Liu, Shiyu ; Han, Minghui ; Li, Fan ; Zhao, Zhigang ; Deng, Li ; Wang, Yi ; Wan, Yajuan ; Chen, Jingru ; Li, Yuanke ; Li, Jiangmei ; Wang, Wei ; Yang, Yi ; Wang, Han ; Zhang, Zhaoyuan ; Cao, Youjia ; Xu, Song ; Zhou, Feilong ; Ma, Wenxuan ; Zhao, Zhen

Background:

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a profoundly immunosuppressive tumor microenvironment, which features a dense desmoplastic stroma enriched with cancer-associated fibroblasts (CAFs) that collectively impede the efficacy of immunotherapies. Although oncolytic viruses (OVs) have demonstrated promising potential in eliciting antitumor immunity, the mechanisms by which stromal components modulate OV efficacy remain poorly understood.

Methods:

To investigate the interplay between immune and stromal components in PDAC following OV treatment, we employed murine and patient-derived tumor models. We characterized immune cell populations using single-cell RNA sequencing and flow cytometry. Functional studies included the engineering of a next-generation oncolytic herpes simplex virus expressing FLT3 ligand, OX40 ligand, and interleukin-12 (IL-12), combined with CD40 agonist antibodies to restore dendritic cell (DC) function and enhance T-cell responses.

Results:

We identified a novel immunosuppressive circuit wherein monocytes, sensing damage-associated molecular patterns and pathogen-associated molecular patterns from OV-infected tumor cells, secrete interleukin-1β. This, in turn, triggers IL-6 production by CAFs, creating an IL-6-rich milieu that impairs DC maturation and co-stimulatory signaling, thereby attenuating T cell-mediated antitumor immunity and restricting OV therapeutic efficacy. Importantly, combination therapy with the engineered OV and CD40 agonist antibodies restored DC functionality and elicited robust tumor-specific T-cell responses in both murine and patient-derived models.

Conclusion:

Our findings reveal a previously unrecognized monocyte-CAF-DC axis that mediates resistance to OV therapy through IL-1β and IL-6-driven suppression of DC function in PDAC. This study provides a mechanistically informed and translationally promising approach to overcome stromal immune suppression, restore effective antitumor immunity, and improve therapeutic outcomes for patients with PDAC.

2017-09-01·Biotechnology letters4区 · 工程技术

Multi-parametric analysis reveals enhanced G2-phase arrest of an optimized anti-HER2 antibody to inhibit breast cancer

4区 · 工程技术

Article

作者: Lang, Xiaoling ; Lv, Ming ; Luo, Longlong ; Geng, Shusheng ; Li, Yan ; Shen, Beifen ; Geng, Jing ; Feng, Jiannan ; Qiao, Chunxia ; Li, Xinying

OBJECTIVES:

To find a "me-better" antibody by epitope-specific antibody optimization and multi-parametric analysis.

RESULTS:

Using epitope-specific library based on the commercial drug, Pertuzumab/2C4, we screened a novel human anti-HER2 antibody, MIL5, which has slightly higher affinity than the drug. MIL5 and 2C4 share the same epitope to bind HER2; however, MIL5 bound to HER2 His235-His245 more tightly than 2C4, which could be the main reason of its enhanced affinity. In vivo experiments also showed MIL5 had stronger anti-cancer activity than 2C4; however, the classical flow cytometry assays to detect cell apoptosis or cycling did not show convincing evidence of the advantages of MIL5. Thus we introduced the multi-parameter in-cell analysis method to evaluate the superiority of MIL5 to 2C4 in arresting cancer cells in G2-phase to inhibit cell growth and/or proliferation.

CONCLUSION:

Multi-parametric method confirmed stronger arrest of G2 by MIL5 to show better anti-cancer function both in vitro and in vivo than 2C4.

2017-05-01·Bioprocess and biosystems engineering3区 · 工程技术

Application of calcium phosphate flocculation in high-density cell culture fluid with high product titer of monoclonal antibody

3区 · 工程技术

Article

作者: Chen, Guoqiang ; Su, Zhiguo ; Li, Feng ; Liu, Hui Fang

The calcium phosphate [Ca₃(PO4)₂] precipitation was used for improving the clarification efficiency in harvest process of the monoclonal antibody (mAb) containing cell culture fluid (CCF) with high turbidity and product titer. The flocculation conditions (concentration, addition order of flocculants, pH, and operation time), and the effect of flocculants on the mAb physical chemical properties (such as distribution of charge variants and aggregates) and process-related impurities removal (such as DNA and CHOP) were evaluated in this study. The results showed that the turbidity of CCF supernatant was significantly reduced at pH 7, 120 min with addition of phosphate ions first, while a high mAb recovery yield was kept in the CCF supernatant after flocculation. Addition of calcium ions at 15-60 mM was sufficient for flocculation in this study. A relationship between turbidity/mAb recovery yield and the concentration of calcium ions was established. More than 85% DNA in the CCF were effectively removed by the addition of optimal concentration of flocculants. Flocculation process of Ca₃(PO4)₂ is an effective pretreatment method in purification processes of mAbs from the CCF with high turbidity and product titer.

442

项与北京天广实生物技术股份有限公司相关的新闻（医药）

2025-12-13

·同写意

百济神州血液管线“三箭齐发”

申请上市临床研究临床结果

2025-12-12

·同写意

2025 ASH：宜明昂科IMM0306联合来那度胺治疗淋巴瘤获积极进展

2025-12-12

·同写意

总额数千万美金！英矽智能与太景达成管线授权合作

临床1期引进/卖出

100 项与北京天广实生物技术股份有限公司相关的药物交易

登录后查看更多信息

100 项与北京天广实生物技术股份有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2026年01月07日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床申请

临床申请批准

临床1期

临床2期

申请上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

重组人源化单抗MIL62（北京诺诚健华） ( CD20 )	狼疮性肾炎更多	临床1/2期
重组人源化单克隆抗体MIL93(北京天广实生物) ( CLDN18.2 )	CLDN18.2阳性胰腺癌更多	临床1/2期
MBS-314 ( BCMA x CD3 x GPRC5D )	难治性多发性骨髓瘤更多	临床1/2期
MBS-303 ( CD20 x CD3 )	CD20阳性的B细胞非霍奇金淋巴瘤更多	临床1/2期
重组人源化双功能单克隆抗体MBS301 ( HER2 )	HER2阳性实体瘤更多	临床1期